Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of Sofosbuvir and Ribavirin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic Genotype 2 or 3 HCV-infection~* Naive to all HCV antiviral treatment(s)~Exclusion Criteria:~* Positive test at Screening for HBsAg, anti-hepatitis B core immunoglobulin M antibody (anti-HBc IgM Ab), or anti-HIV Ab~* History of any other clinically significant chronic liver disease~* A history consistent with decompensated liver disease~* History or current evidence of psychiatric illness, immunologic disorder, hemoglobinopathy, pulmonary or cardiac disease, seizure disorder or anticonvulsant use, poorly controlled diabetes, cancer, or a history of malignancy, that makes the subject unsuitable for the study.~* Participation in a clinical study within 3 months prior to first dose

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sofosbuvir+RBV (Type: EXPERIMENTAL): Participants were randomized to receive sofosbuvir+RBV for 12 weeks.
- PEG+RBV (Type: ACTIVE_COMPARATOR): Participants were randomized to receive PEG+RBV for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).